Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer

NCT01861197 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Squamous NSCLC

Interventions

DRUG: Dovitinib

Sponsor

Samsung Medical Center